Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236700 | 0.86 | MAPK8 (0.38) | MAPK8PTGDR2MAPTTP53KDM4E | |
| SCHEMBL16250040 | 0.81 | CNR2 (0.46) | KDM4EMAPK1HTTNPSR1ALDH1A1 | |
| SCHEMBL3517138 | 0.80 | MEN1 (0.42) | PTGDR2MAPTTP53KDM4EMAPK1 | |
| SCHEMBL3516700 | 0.76 | MEN1 (0.40) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL15170677 | 0.73 | USP2 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL13461591 | 0.72 | CNR2 (0.45) | KDM4EHTTALDH1A1CNR1CNR2 | |
| SCHEMBL13461639 | 0.72 | KDM4E (0.52) | KDM4EHTTALDH1A1CNR1CNR2 | |
| SCHEMBL15170497 | 0.72 | ADORA1 (0.31) | — | |
| SCHEMBL13461638 | 0.71 | PTGS1 (0.42) | KDM4EMAPK1HTTNPSR1ALDH1A1 | |
| SCHEMBL13461636 | 0.71 | MAPT (0.39) | MAPTKDM4EMAPK1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-10-26 | — | — | US | disclosed |
| US-9676771-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014186398-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | MAPK8 157/4885PTGDR2 3473/4885MAPT 4697/4885 |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | MAPK8 157/4885PTGDR2 3473/4885MAPT 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.